ASTRO: Novel adjuvant approach ‘encouraging’ for pancreatic cancer
November 9, 2015|Hematology and Oncology
Author and Disclosure Information
AT THE ASTRO ANNUAL MEETING
“Future questions are whether SBRT should be given prior to or after chemotherapy,” Dr. Herman said. There is also the question of what the target area should be and if higher doses of SBRT would be needed.
The study was supported by the Viragh Family Foundation and the Gonzalez and McKnight Family Foundation, with partial funding by Aduro, which manufactures the tumor cell vaccine used in the study. Dr. Herman did not report having personal disclosures.
